This demonstration of the activation of the NLRP3 inflammasome in multiple in vivo and in vitro models of ALS, and the subsequent reduction in IL-1β secretion with an NLRP3 inhibitor suggests a commonality that may potentially be utilized as a novel target for therapeutics. This evidence concerns the gene NLRP3 and amyotrophic lateral sclerosis.